Private equity firm taps ex-Editas CEO Jim Mullen to help expand pharma portfolio — with a nod to cell, gene therapies

Jim Mullen is lending his years of biotech CEO experience — from Biogen, Patheon and Editas — to the private equity firm Advent International.

Advent managing partner …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pri­vate eq­ui­ty firm taps ex-Ed­i­tas CEO Jim Mullen to help ex­pand phar­ma port­fo­lio — with a nod to cell, gene ther­a­pies